Continuous Interscalene Block vs Liposomal Bupivacaine After Proximal

Status Recruiting

Clinical Trial Summary

The purpose of this study is to compare the efficacy of continuous interscalene block (CISB) using standard bupivacaine versus a single interscalene injection of liposomal bupivacaine (LB) on pain control following surgical fixation of proximal humerus fractures.

Clinical Trial Description

Restricted range of motion following open reduction and internal fixation (ORIF) of proximal humerus fractures is a potential complication that severely limits functional outcomes . It must therefore be avoided by adequate pain control in order to allow for early mobilisation in addition to physiotherapy. Interscalene block (ISB) is one of the most effective and widely used regional analgesic options shoulder surgeries. ISB can be delivered as a single injection or by continuous infusion via an indwelling catheter. While continuous interscalene block (CISB) offers a longer duration of analgesia as compared to a single injection of the same anaesthetic, it carries an inherent risk of catheter malposition, dislodgement, and infection. As compared to standard bupivacaine (SB), liposomal bupivacaine (LB) is a formulation designed to prolong the duration of analgesia up to 72 hours via a single injection. While this could avoid the need for an indwelling catheter, results of studies comparing LB to CISB have been inconsistent. The purpose of this is non-inferiority trial is to compare the effectiveness of a single injection of LB versus CISB with SB on pain control following ORIF of proximal humerus fractures. The study hypothesis is that LB is not unacceptably worse than CISB with regard to pain control in the first two postoperative days. Patients providing informed consent will be screened for eligibility. All eligible patients will be randomly assigned in a double-blind manner (participant and investigator) and a 1:1 ratio to receive either LB or CISB. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05084573
Study type	Interventional
Source	The University of Hong Kong
Contact	Chi Wing Chan
Phone	22551740
Email	timmychancw@gmail.com
Status	Recruiting
Phase	Phase 3
Start date	August 1, 2020
Completion date	March 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT04003272` - MDR - Comprehensive Reverse/Versa Dial Ti Glenosphere
Active, not recruiting	`NCT02944058` - Plate Fixation Versus Intramedullary Nailing of 3 and 4 Part Proximal Humerus Fractures	N/A
Withdrawn	`NCT00741182` - Effect of PTH(1-34) Treatment on Fracture Healing in Vivo	Phase 2
Completed	`NCT03217344` - Conservative Treatment of Proximal Humeral Fractures	N/A
Recruiting	`NCT02609906` - Operative Treatment of 2-fragment-fractures (AO 11-A3) of the Proximal Humerus in the Elderly: Cement Augmented Locking Plate Philos vs. Proximal Humerus Nail MultiLoc	N/A
Active, not recruiting	`NCT05302089` - Rehabilitation Following Displaced Proximal Humerus Fractures	N/A
Completed	`NCT02836366` - Targon PH+ Follow-Up
Recruiting	`NCT01687374` - Parathyroid Hormone for the Treatment of Humerus Fractures	Phase 4
Recruiting	`NCT04928664` - Continuous vs Liposomal Bupivacaine Interscalene Block for Proximal Humeral Fracture (CLIP)	Phase 4
Completed	`NCT02539173` - Diagnosis of Diaphragmatic Paralysis After Interscalene Block: Feasibility and Impact Observed	N/A
Recruiting	`NCT04984291` - Zimmer Biomet Shoulder Arthroplasty PMCF	N/A
Not yet recruiting	`NCT06357143` - Efficacy of Early Multimodal Physiotherapy in Patients With Reverse Shoulder Prosthesis	N/A
Recruiting	`NCT02913378` - Conservative vs Surgical Treatment for Proximal Humerus Fractures in the Elderly	N/A
Enrolling by invitation	`NCT04003311` - MDR - Comprehensive Primary/Micro Stem & Versa-Dial Ti Humeral Head
Recruiting	`NCT04651543` - X-Ray Follow-up in Proximal Humeral Fractures Conservatively Treated
Not yet recruiting	`NCT04507880` - A 2-Year Prospective Follow-up Study of the Global Unite Reverse Fracture Shoulder System for Proximal Humerus Fractures	N/A
Terminated	`NCT03599336` - RSA vs. Nonop for 3 & 4-Part Proximal Humerus Fractures	N/A
Recruiting	`NCT05284357` - Post Market Clinical Follow-up Study for Arthroplasty Shoulder System of FX Solutions at the Long Term
Not yet recruiting	`NCT06360887` - Management of Proximal Humerus Fractures in Adults: a Clinical Trial

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Continuous Interscalene Block vs Liposomal Bupivacaine After Proximal Humerus Fracture Surgery — CLIP-H

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms